LYON, France--(BUSINESS WIRE)--Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announces its half-year report on the liquidity contract with the firm Kepler Cheuvreux and an increase of €50,000 to the resources allocated to the contract, in accordance with the provisions of article 4 of AMF decision no. 2021-01 of June 22, 2021.
Under the liquidity contract entered into between Maat Pharma and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th, 2024:
- 26,929 shares
- € 17,089.40
- Number of executions on buy side on semester: 933
- Number of executions on sell side on semester: 1,014
- Traded volume on buy side on semester: 28,959 shares for € 237,891.32
- Traded volume on sell side on semester: 26,266 shares for € 220,168.07
As a reminder:
- the following resources appeared on the last half year statement on December 31, 2023 on the liquidity account:
- 24,236 shares
- € 34,107.60
- Number of executions on buy side on semester: 627
- Number of executions on sell side on semester: 368
- Traded volume on buy side on semester: 18,328 shares for € 122,340.49
- Traded volume on sell side on semester: 9,576 shares for € 64,693.03
- the following resources appeared on the liquidity account when the activity started:
- 0 shares
- € 200,000.00
Following the addition of these resources for the amount of €50,000, the position on July 4th, 2024, is:
- 26,006 shares
- € 74,303.08
The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.
Buy Side | Sell Side | ||||||
Number of executions |
Number of shares |
Traded volume in EUR |
Number of executions |
Number of shares |
Traded volume in EUR |
||
Total | 933 |
28,959 |
237,891.32 |
1,014 |
26,266 |
220,168.07 |
|
02/01/2024 | - |
- |
- |
9 |
102 |
719.10 |
|
03/01/2024 | 3 |
60 |
448.80 |
15 |
435 |
3,275.55 |
|
04/01/2024 | 9 |
126 |
948.78 |
8 |
211 |
1,612.04 |
|
05/01/2024 | 2 |
45 |
339.30 |
3 |
90 |
689.40 |
|
08/01/2024 | 18 |
410 |
2,886.40 |
- |
- |
- |
|
09/01/2024 | 11 |
340 |
2,237.20 |
15 |
425 |
2,843.25 |
|
10/01/2024 | 5 |
130 |
877.50 |
2 |
72 |
487.44 |
|
11/01/2024 | 2 |
2 |
13.74 |
10 |
241 |
1,679.77 |
|
12/01/2024 | 4 |
50 |
351.00 |
2 |
70 |
501.20 |
|
15/01/2024 | 8 |
203 |
1,408.82 |
8 |
110 |
779.90 |
|
16/01/2024 | 3 |
36 |
252.00 |
3 |
35 |
246.40 |
|
17/01/2024 | 5 |
70 |
482.30 |
- |
- |
- |
|
18/01/2024 | 5 |
151 |
1,026.80 |
- |
- |
- |
|
19/01/2024 | 10 |
222 |
1,469.64 |
1 |
30 |
201.00 |
|
22/01/2024 | 3 |
50 |
351.00 |
27 |
641 |
4,512.64 |
|
23/01/2024 | - |
- |
- |
5 |
93 |
672.39 |
|
24/01/2024 | 7 |
175 |
1,242.50 |
4 |
130 |
928.20 |
|
25/01/2024 | 5 |
71 |
506.94 |
2 |
36 |
257.76 |
|
26/01/2024 | 3 |
10 |
71.50 |
4 |
93 |
668.67 |
|
29/01/2024 | 7 |
141 |
1,022.25 |
8 |
155 |
1,148.55 |
|
30/01/2024 | 2 |
21 |
151.20 |
2 |
36 |
260.64 |
|
31/01/2024 | 4 |
110 |
784.30 |
6 |
148 |
1,061.16 |
|
01/02/2024 | 3 |
60 |
430.80 |
2 |
42 |
304.50 |
|
02/02/2024 | 8 |
160 |
1,142.40 |
8 |
150 |
1,087.50 |
|
05/02/2024 | - |
- |
- |
2 |
35 |
250.95 |
|
06/02/2024 | 3 |
70 |
497.00 |
5 |
105 |
753.90 |
|
07/02/2024 | 4 |
85 |
606.05 |
- |
- |
- |
|
08/02/2024 | 2 |
21 |
149.94 |
5 |
83 |
593.45 |
|
09/02/2024 | 10 |
185 |
1,311.65 |
6 |
118 |
859.04 |
|
12/02/2024 | 7 |
127 |
896.62 |
1 |
1 |
7.22 |
|
13/02/2024 | 1 |
1 |
7.02 |
4 |
24 |
169.44 |
|
14/02/2024 | 4 |
69 |
481.62 |
2 |
32 |
227.20 |
|
15/02/2024 | 3 |
26 |
182.52 |
10 |
151 |
1,069.08 |
|
16/02/2024 | 2 |
30 |
213.00 |
3 |
41 |
293.15 |
|
19/02/2024 | 7 |
130 |
928.20 |
17 |
280 |
2,027.20 |
|
20/02/2024 | - |
- |
- |
15 |
329 |
2,470.79 |
|
21/02/2024 | 9 |
130 |
964.60 |
- |
- |
- |
|
22/02/2024 | - |
- |
- |
9 |
115 |
865.95 |
|
23/02/2024 | 1 |
1 |
7.62 |
53 |
1,131 |
9,398.61 |
|
26/02/2024 | 26 |
550 |
4,526.50 |
9 |
103 |
850.78 |
|
27/02/2024 | 6 |
75 |
612.00 |
13 |
277 |
2,310.18 |
|
28/02/2024 | 45 |
880 |
6,758.40 |
23 |
706 |
5,655.06 |
|
29/02/2024 | 15 |
211 |
1,673.23 |
3 |
34 |
270.30 |
|
01/03/2024 | 4 |
90 |
711.00 |
10 |
200 |
1,606.00 |
|
04/03/2024 | 14 |
260 |
2,048.80 |
7 |
130 |
1,036.10 |
|
05/03/2024 | 9 |
162 |
1,263.60 |
10 |
133 |
1,046.71 |
|
06/03/2024 | 11 |
245 |
2,035.95 |
53 |
1,009 |
8,465.51 |
|
07/03/2024 | 2 |
20 |
170.40 |
21 |
260 |
2,236.00 |
|
08/03/2024 | 17 |
335 |
2,814.00 |
6 |
94 |
797.12 |
|
11/03/2024 | 7 |
114 |
992.94 |
22 |
381 |
3,341.37 |
|
12/03/2024 | 7 |
139 |
1,234.32 |
10 |
316 |
2,837.68 |
|
13/03/2024 | 1 |
35 |
315.00 |
25 |
1,039 |
9,735.43 |
|
14/03/2024 | 30 |
921 |
8,427.15 |
13 |
319 |
2,992.22 |
|
15/03/2024 | 11 |
291 |
2,697.57 |
28 |
632 |
5,890.24 |
|
18/03/2024 | 5 |
99 |
903.87 |
3 |
45 |
413.55 |
|
19/03/2024 | - |
- |
- |
6 |
74 |
682.28 |
|
20/03/2024 | 20 |
553 |
4,943.82 |
13 |
328 |
2,971.68 |
|
21/03/2024 | 8 |
370 |
3,204.20 |
3 |
55 |
480.70 |
|
22/03/2024 | 6 |
125 |
1,113.75 |
19 |
422 |
3,798.00 |
|
25/03/2024 | 12 |
193 |
1,796.83 |
16 |
481 |
4,540.64 |
|
26/03/2024 | 6 |
158 |
1,448.86 |
8 |
173 |
1,600.25 |
|
27/03/2024 | 1 |
50 |
465.00 |
6 |
258 |
2,414.88 |
|
28/03/2024 | 22 |
692 |
6,304.12 |
8 |
343 |
3,217.34 |
|
02/04/2024 | 5 |
185 |
1,626.15 |
6 |
185 |
1,635.40 |
|
03/04/2024 | 4 |
56 |
495.60 |
1 |
1 |
8.86 |
|
04/04/2024 | - |
- |
- |
4 |
90 |
808.20 |
|
05/04/2024 | - |
- |
- |
17 |
435 |
4,023.75 |
|
08/04/2024 | 9 |
256 |
2,403.84 |
26 |
626 |
5,959.52 |
|
09/04/2024 | 8 |
133 |
1,263.50 |
10 |
444 |
4,253.52 |
|
10/04/2024 | - |
- |
- |
7 |
226 |
2,171.86 |
|
11/04/2024 | 2 |
36 |
342.00 |
5 |
33 |
316.47 |
|
12/04/2024 | 2 |
20 |
189.60 |
1 |
1 |
9.56 |
|
15/04/2024 | 41 |
1,314 |
12,246.48 |
25 |
785 |
7,622.35 |
|
16/04/2024 | 4 |
125 |
1,140.00 |
14 |
325 |
2,996.50 |
|
17/04/2024 | 13 |
578 |
5,138.42 |
- |
- |
- |
|
18/04/2024 | 3 |
101 |
906.98 |
5 |
266 |
2,420.60 |
|
19/04/2024 | 21 |
1,779 |
15,726.36 |
7 |
304 |
2,723.84 |
|
22/04/2024 | 4 |
330 |
2,864.40 |
11 |
593 |
5,200.61 |
|
23/04/2024 | 3 |
124 |
1,088.72 |
6 |
157 |
1,389.45 |
|
24/04/2024 | 6 |
217 |
1,907.43 |
2 |
2 |
17.62 |
|
25/04/2024 | 1 |
1 |
8.80 |
12 |
468 |
4,165.20 |
|
26/04/2024 | 2 |
130 |
1,170.00 |
3 |
29 |
262.74 |
|
29/04/2024 | 6 |
285 |
2,676.15 |
20 |
652 |
6,109.24 |
|
30/04/2024 | 6 |
354 |
3,313.44 |
3 |
105 |
996.45 |
|
02/05/2024 | 5 |
221 |
2,048.67 |
2 |
80 |
747.20 |
|
03/05/2024 | 1 |
1 |
9.24 |
7 |
264 |
2,460.48 |
|
06/05/2024 | 10 |
323 |
3,007.13 |
4 |
91 |
849.94 |
|
07/05/2024 | 4 |
244 |
2,286.28 |
12 |
466 |
4,385.06 |
|
08/05/2024 | 1 |
20 |
188.00 |
1 |
5 |
47.30 |
|
09/05/2024 | - |
- |
- |
1 |
95 |
898.70 |
|
10/05/2024 | 6 |
161 |
1,513.40 |
2 |
39 |
368.94 |
|
13/05/2024 | 2 |
103 |
968.20 |
2 |
101 |
952.43 |
|
14/05/2024 | 2 |
77 |
719.18 |
2 |
84 |
788.76 |
|
15/05/2024 | 55 |
3,305 |
27,695.90 |
5 |
150 |
1,281.00 |
|
16/05/2024 | 7 |
340 |
2,692.80 |
9 |
260 |
2,072.20 |
|
17/05/2024 | 12 |
387 |
3,154.05 |
15 |
325 |
2,668.25 |
|
20/05/2024 | 8 |
325 |
2,665.00 |
7 |
205 |
1,693.30 |
|
21/05/2024 | 7 |
265 |
2,130.60 |
4 |
200 |
1,624.00 |
|
22/05/2024 | 11 |
344 |
2,752.00 |
3 |
88 |
719.84 |
|
23/05/2024 | 3 |
62 |
494.76 |
6 |
130 |
1,040.00 |
|
24/05/2024 | 6 |
308 |
2,439.36 |
8 |
230 |
1,826.20 |
|
27/05/2024 | 1 |
15 |
119.10 |
2 |
80 |
640.80 |
|
28/05/2024 | 2 |
70 |
558.60 |
3 |
55 |
443.30 |
|
29/05/2024 | 8 |
212 |
1,704.48 |
5 |
129 |
1,046.19 |
|
30/05/2024 | 8 |
313 |
2,500.87 |
4 |
88 |
709.28 |
|
31/05/2024 | 8 |
451 |
3,598.98 |
1 |
1 |
8.04 |
|
03/06/2024 | 3 |
150 |
1,194.00 |
3 |
50 |
400.00 |
|
04/06/2024 | 6 |
200 |
1,586.00 |
4 |
110 |
875.60 |
|
05/06/2024 | 5 |
119 |
940.10 |
5 |
100 |
794.00 |
|
06/06/2024 | 7 |
250 |
1,970.00 |
1 |
1 |
7.94 |
|
07/06/2024 | 6 |
214 |
1,697.02 |
8 |
140 |
1,113.00 |
|
10/06/2024 | 9 |
305 |
2,400.35 |
1 |
40 |
316.80 |
|
11/06/2024 | 5 |
200 |
1,560.00 |
5 |
212 |
1,670.56 |
|
12/06/2024 | 3 |
105 |
807.45 |
1 |
50 |
385.00 |
|
13/06/2024 | 5 |
163 |
1,253.47 |
4 |
125 |
965.00 |
|
14/06/2024 | 17 |
440 |
3,291.20 |
2 |
57 |
434.91 |
|
17/06/2024 | 26 |
700 |
4,704.00 |
6 |
285 |
1,915.20 |
|
18/06/2024 | 3 |
60 |
403.80 |
7 |
355 |
2,410.45 |
|
19/06/2024 | 10 |
591 |
3,953.79 |
3 |
39 |
267.54 |
|
20/06/2024 | 4 |
68 |
450.84 |
7 |
150 |
1,009.50 |
|
21/06/2024 | 2 |
51 |
346.80 |
5 |
303 |
2,084.64 |
|
24/06/2024 | 1 |
19 |
131.10 |
7 |
174 |
1,211.04 |
|
25/06/2024 | 7 |
150 |
1,081.50 |
10 |
360 |
2,610.00 |
|
26/06/2024 | - |
- |
- |
26 |
944 |
7,174.40 |
|
27/06/2024 | 19 |
613 |
4,677.19 |
4 |
89 |
688.86 |
|
28/06/2024 | 23 |
904 |
6,535.92 |
4 |
187 |
1,357.62 |
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).